{
  "id": 19532349,
  "title": "After CAR-T Failure in Diffuse Large B-Cell Lymphoma, What Comes Next?",
  "url": "https://urgent.news/2026/11/11/after-car-t-failure-in-diffuse-large-b-cell-lymphoma-what-comes-next",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-11T17:41:09.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/spotlight/dlbcl/123832"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- CD19-targeted chimeric antigen receptor (CAR) T-cells have emerged as a second- and later-line treatment strategy for patients with diffuse large B-cell lymphoma (DLBCL), with three FDA-approved products. \"Across CAR T-cell...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}